肺高血圧症に関するトピック
Alexander Kaysin1, Sunil Swami2, Oluwatoni Aluko2
1University of Maryland (UM) Capital Region Health Family Medicine Residency Program in Largo, MD.
FP essentials
|January 13, 2026
まとめ
肺高血圧症(PH)は、心エコー検査と右心カテーテル検査によって診断される重篤な状態です。早期の予防と、新規薬物療法を含む標的療法は、患者の転帰を改善します。
科学分野:
- 循環器科
- 呼吸器科
- 内科
背景:
- 肺高血圧症(PH)は、肺動脈圧が高い進行性の疾患です。
- 早期診断は、呼吸困難や疲労などの症状の認識に依存し、心エコー検査が主要なツールとなります。
研究 の 目的:
- PHの診断基準(心エコー検査および右心カテーテル検査を含む)を概説すること。
- PHの一次予防および二次予防戦略を詳述すること。
- 肺動脈性肺高血圧症(PAH)の現在および今後の薬物療法をレビューすること。
主な方法:
- 診断は右心カテーテル検査(平均肺動脈圧≧20 mm Hg、肺血管抵抗>2 Wood単位)によって確認されます。
- 予防戦略には、ライフスタイルの変更、危険因子管理(高血圧、糖尿病)、および環境曝露管理が含まれます。
- 薬物療法レビューには、エンドセリン、プロスタサイクリン、一酸化窒素経路の標的化が含まれます。
主要な成果:
- 肺動脈性肺高血圧症の転帰は、特定の経路を標的とする薬物療法の進歩によって改善されています。
- 中等症から重症の疾患には併用療法が推奨され、末梢性プロスタノイドは重症PAHに用いられます。
- 右心不全の管理には、体液管理、利尿薬、肺移植または緩和的処置の検討が含まれます。
結論:
- 肺高血圧症の効果的な管理には、早期の疑い、正確な診断、および包括的な予防戦略が必要です。
- 新規薬物療法は、疾患の重症度に合わせて調整された併用療法および高度な治療により、転帰を改善します。
- 栄養や右心不全などの合併症の管理を含む、統合的な支持療法は、PH患者にとって不可欠です。
さらに関連する動画
関連する概念動画
Pulmonary Hypertension: Classification and Pathogenesis
567
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
567
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
584
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
584
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
457
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
457
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
438
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
438
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
554
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
554
Other Pulmonary Disorders
1.5K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.5K


